Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 03, 2010
Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
Myriad remains bullish about its business expansion and revenue growth prospects, despite several ongoing events outside its control that stand to impact its business.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010 / Pharmacogenomics Reporter - US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo
November 3, 2010 / Pharmacogenomics Reporter - Myriad Updates Investors on Companion Dx Deals, EU Expansion, and Capturing Asymptomatic Market
March 10, 2010 / Pharmacogenomics Reporter - Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 2, 2012 / Pharmacogenomics Reporter - Will Insurers Cover $700 for Myriad's Large Rearrangement Test Plus $3K for BRACAnalysis?
August 15, 2012 / Pharmacogenomics Reporter